As of Nov 19, 2026, 0 of 1 active firms rate PAHC a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
PAHC EPS & revenue forecast
EPS · NEXT QUARTER
$0.87
Range $0.84 – $0.89 · 2 analysts · +14% YoY
Next period, 2 analysts expect Phibro Animal Health Corporation to earn $0.87 a share (range $0.84 – $0.89), versus $0.76 a year earlier. Full-year consensus is $3.48, growing to $3.88 the year after.
REVENUE · NEXT QUARTER
$397.0M
Range $397.0M – $397.0M · 2 analysts · +4% YoY
Revenue is expected to reach $397.0M (range $397.0M – $397.0M), +3.5% year-over-year. Full-year consensus is $1.6B, rising to $1.6B next year.
Top analysts covering Phibro Animal Health Corporation
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PAHC.
#1
Erin Wright
Morgan Stanley · Rank #81
Neutral
$49.00+37.6% to target
Overall win rate
55%
+ Follow
#2
Balaji Prasad
Barclays · Rank #226
Sell
$22.00-38.2% to target
Overall win rate
45%
+ Follow
#3
Daniel Grosslight
Citigroup
Neutral
$44.00+23.5% to target
Coverage
—
+ Follow
#4
EK
Ekaterina Knyazkova
JP Morgan
Buy
$50.00+40.4% to target
Coverage
—
+ Follow
#5
NT
Navann Ty
Exane BNP Paribas
Neutral
$37.00+3.9% to target
Coverage
—
+ Follow
PAHC stock forecast FAQ
What is PAHC's average 12-month price target?+
The 1 active firms with a live target average $44.00 for Phibro Animal Health Corporation over the next 12 months, ranging from a $44.00 high to a $44.00 low, as of Nov 19, 2026.
Is PAHC stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 1 active firms as of Nov 19, 2026, 0 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover PAHC?+
1 active firms have a recognized rating on Phibro Animal Health Corporation as of Nov 19, 2026, and 1 active firms carry a live 12-month price target.
Who is the most accurate analyst covering PAHC?+
Among analysts who currently cover PAHC, Erin Wright of Morgan Stanley has the strongest overall Quantellect track record (Rank #81). Their current call is Neutral with a $49.00 target.
What is Phibro Animal Health Corporation's projected EPS for next quarter?+
The consensus estimate is $0.87 per share (range $0.84 – $0.89) across 2 analysts. Full-year EPS is projected at $3.48, rising to $3.88 the following year.
How much revenue is Phibro Animal Health Corporation expected to report next quarter?+
Consensus revenue is $397.0M (range $397.0M – $397.0M). Full-year revenue is projected at $1.6B, growing to $1.6B next year.
Have analysts been upgrading or downgrading PAHC lately?+
As of Nov 19, 2026, 0 of 1 active firms rate PAHC a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PAHC calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.